Uterine Fibroids in India: Diagnosis and Treatment Options

• Fibroids are benign (non-cancerous) muscle growths in the uterus — cancer (leiomyosarcoma) occurs in fewer than 0.1% of cases.
• Symptoms, not size, decide treatment. Many fibroids are silent and only need an annual scan.
• Heavy bleeding can often be controlled without surgery using tranexamic acid, hormonal pills or a Mirena IUD.
• Uterus-sparing options — myomectomy, uterine artery embolisation, focused ultrasound — suit women who want to keep their uterus or plan pregnancy.
• Hysterectomy is the only permanent cure but sits late in the ladder for most women.
• Fibroids almost always shrink after menopause, so age and timing matter in the decision.

Uterine fibroids (also called leiomyomas or myomas — the words mean the same thing) are benign growths of smooth muscle that develop in or on the wall of the uterus. They are estrogen-responsive: they usually appear after the late 20s, can grow during the reproductive years, and tend to shrink after menopause when estrogen falls. They are almost never cancerous — leiomyosarcoma occurs in fewer than 0.1% of cases.

Fibroids are very common. Indian ultrasound studies suggest roughly 20–30% of women over 30 have at least one fibroid, rising towards 40% by the mid-40s. Many are found by chance during a scan done for another reason. Only about a quarter to a third of women with fibroids have symptoms troublesome enough to need treatment — so clinically significant fibroids affect a smaller share of women than the raw prevalence figures suggest.

Where a fibroid sits matters more than how big it is. Submucosal fibroids bulge into the uterine cavity, intramural fibroids sit within the muscle wall, subserosal fibroids grow on the outer surface, and pedunculated fibroids hang on a stalk. A small submucosal fibroid can cause heavy bleeding, while a large subserosal one may cause no symptoms at all. Indian ultrasound and MRI reports now commonly use the FIGO classification (types 0–8) to describe location.

Known risk factors include never having been pregnant, early first period, obesity, and a family history of fibroids; prevalence is higher in women of African descent. Vitamin D deficiency — very common in India — is also linked with higher fibroid risk in some studies. Pregnancy and breastfeeding appear protective.

Heavy menstrual bleeding is the most common symptom. Periods may be heavier than before, last longer, or pass clots. Persistent heavy loss often leads to iron-deficiency anaemia, which causes tiredness, breathlessness and poor concentration and needs its own treatment alongside the fibroid. If your bleeding is the main problem, our detailed guide to heavy menstrual bleeding covers measurement and the full treatment ladder.

Bulk or pressure symptoms come from larger fibroids pressing on neighbouring organs: lower-abdominal heaviness, needing to pass urine more often (pressure on the bladder), constipation (pressure on the bowel), backache, or feeling a firm lump in the lower belly. Pain is less common — most fibroids do not hurt unless they outgrow their blood supply (degeneration), twist on a stalk, or sit alongside Adenomyosis vs Endometriosis: Differences, Diagnosis & Treatment. For period pain in general, see our guide to painful periods.

Effect on fertility and pregnancy depends on location. Submucosal fibroids — and intramural fibroids that distort the cavity — can lower fertility and raise the risk of miscarriage, so they may be worth removing before trying to conceive. Subserosal fibroids generally do not affect fertility. In pregnancy, fibroids can occasionally cause pain from degeneration, affect the baby's position, or rarely obstruct delivery. If pregnancy has not come despite trying, our guide to secondary infertility may help.

Treatment is offered when fibroids cause heavy bleeding with anaemia, significant pressure or urinary symptoms, fertility problems or recurrent miscarriage, severe pain, or rapid growth. Fibroids found by chance that cause no symptoms usually need only watchful waiting with an annual ultrasound — treating a silent fibroid 'just in case' is generally not warranted and exposes you to needless risk.

A pelvic examination by a gynaecologist often reveals an enlarged or irregular uterus that suggests fibroids. The first-line test is a transvaginal ultrasound, which maps the number, size and location of fibroids. It costs roughly ₹1,000–3,000 in private centres and is free or minimal at government hospitals.

Saline infusion sonography (also called hysterosonography) gently fills the uterine cavity with saline to show submucosal fibroids more clearly and costs around ₹3,000–6,000 — useful in a fertility workup. Hysteroscopy (about ₹8,000–20,000 as an outpatient) looks directly inside the cavity and can sometimes remove a small submucosal fibroid in the same sitting.

A pelvic MRI (about ₹6,000–12,000) gives the most detailed map and is used before complex surgery, before uterine artery embolisation, when ultrasound is unclear, when adenomyosis is suspected, or in the rare case where sarcoma is being considered. Most straightforward fibroid cases do not need an MRI.

Blood tests usually include a complete blood count and serum ferritin (to detect and gauge iron-deficiency anaemia from heavy bleeding), thyroid function (an underactive thyroid can also cause heavy periods), and a pregnancy test where relevant. Women heading for surgery have additional pre-operative checks — blood group, kidney and liver function, and clotting.

Tranexamic acid (Indian brands include Pause, Trapic, Lupisac) at 500–1,000 mg three times daily during the heaviest 3–5 days of a period is first-line for fibroid-related heavy bleeding. It cuts blood loss by roughly 40–50%, is non-hormonal, can be combined with NSAIDs, and costs about ₹50–200 per cycle. It is avoided in women with a history of blood clots or active vascular disease.

NSAIDs such as mefenamic acid (500 mg three times daily) or ibuprofen (400–600 mg three times daily) modestly reduce both bleeding and pain, especially when started a day before the period is due. They are often paired with tranexamic acid.

Combined oral contraceptive pills can reduce bleeding by 30–50% and add cycle regularity and contraception, though they do not shrink fibroids. They are avoided in women with migraine with aura, smokers over 35, and those with uncontrolled high blood pressure or a clot history. Our guide to birth control pills in India explains who they suit.

The levonorgestrel-releasing IUD (Mirena) is one of the most effective non-surgical options, reducing bleeding by 70–95% over six months while providing 5–8 years of contraception. It works best when the cavity is not badly distorted; the device is more likely to be expelled in a fibroid uterus, especially with submucosal fibroids, so careful ultrasound mapping helps with selection. For a plain comparison of devices, see copper IUD vs Mirena.

GnRH agonists (leuprolide/Lupride, goserelin/Zoladex) temporarily switch off the ovaries' estrogen production. Monthly injections cost about ₹3,500–8,000. Fibroids typically shrink 35–65% over 3–6 months, bleeding falls sharply, and anaemia improves. Use is limited to about six months because the low-estrogen state causes hot flushes, mood changes, vaginal dryness and bone loss.

Their main role is as a bridge before surgery — shrinking a fibroid so a less invasive approach becomes possible, and giving iron stores time to recover — or for short-term control near menopause. They are not a long-term solution because fibroids regrow quickly once the drug stops.

Ulipristal acetate (Esmya), a selective progesterone receptor modulator that shrinks fibroids and reduces bleeding, has had its use restricted internationally because of rare but serious liver injury. Where available in India in 2026 it requires liver-function monitoring under specialist supervision.

Newer oral GnRH antagonist combinations (such as relugolix with low-dose estradiol and norethisterone, marketed internationally as Myfembree) are reaching the Indian market. Adding a little estrogen back protects bone and allows longer use than older injectables, with no injections needed. In 2026, cost — roughly ₹8,000–15,000 a month — keeps access limited.

Uterine artery embolisation is performed by an interventional radiologist, who threads a thin catheter (usually from the wrist or groin) into the uterine arteries and injects tiny particles to block the fibroid's blood supply, causing it to shrink. It spares the uterus, is less invasive than surgery, can treat several fibroids in one sitting, and has a recovery of about 1–2 weeks. In private hospitals in 2026 it costs roughly ₹1.5–3 lakh.

UAE typically reduces fibroid volume by 40–60% over 6–12 months, cuts bleeding by 80–90%, and eases bulk symptoms. Symptom improvement is reported in around 80–90% of well-selected women. A repeat procedure or further treatment is needed in roughly 10–20% of cases over five years.

It suits women who want to avoid hysterectomy and have completed their family or do not plan pregnancy. Pregnancy after UAE is possible but carries higher risks of placental problems, growth restriction and preterm birth, so women hoping to conceive soon are usually steered towards myomectomy instead.

UAE is not done in pregnancy, active pelvic infection, or when the diagnosis is uncertain; very large fibroids and pedunculated subserosal fibroids are relative cautions. Side effects include post-embolisation syndrome (a few days of pain, fever and fatigue) and, rarely, infection or ovarian failure that may ultimately need surgery.

Myomectomy removes the fibroids but keeps the uterus, making it the preferred surgery for women who want a future pregnancy or wish to keep their uterus. It can be done through an open abdominal incision, by laparoscopy (with or without robotic assistance), or hysteroscopically for fibroids inside the cavity.

Open abdominal myomectomy suits very large or numerous fibroids, or awkward positions. It uses a bikini-line or vertical incision, costs about ₹50,000–1.5 lakh in private hospitals, and needs a 4–7 day stay and 4–6 weeks of recovery. Government tertiary centres such as AIIMS perform it routinely at minimal cost for eligible patients.

Laparoscopic myomectomy, done through keyhole incisions, suits moderate fibroids in accessible positions and offers a shorter stay (1–3 days), faster recovery (2–3 weeks) and less pain. It costs roughly ₹80,000–2.5 lakh privately, with robotic assistance adding more. Surgeon experience matters — choose a high-volume gynaecological surgeon.

Hysteroscopic myomectomy removes submucosal fibroids through the cervix with no abdominal cut — a 30–60 minute day-care procedure costing about ₹25,000–60,000 with recovery measured in days. It only suits FIGO type 0–2 fibroids of moderate size. Whichever route is used, fibroids recur in about 15–30% of women over 5–10 years because the underlying tendency remains, and a later pregnancy may need a caesarean depending on how deep the uterine repair was.

Removing the uterus removes the disease entirely, so hysterectomy is the only permanent cure. It is considered when symptoms are severe, other options have failed or do not suit, fibroids are very large or numerous, the family is complete, and the woman wants a permanent resolution. Fibroids are among the leading reasons hysterectomy is performed in India.

It can be done as a total abdominal hysterectomy (open, for a very large uterus), a vaginal hysterectomy (through the vagina, with no abdominal scar and faster recovery), or laparoscopically or robotically (keyhole, low blood loss, quick recovery). The route depends on uterine size, surgeon expertise and your preference.

Costs vary widely: government tertiary centres (AIIMS, PGI Chandigarh, JIPMER, CMC Vellore) charge little or nothing for eligible patients, while private hospitals charge about ₹1–3 lakh in 2026. Ayushman Bharat PM-JAY covers hysterectomy for eligible families at empanelled hospitals, and CGHS, ECHS and ESI cover their members.

In a premenopausal woman the ovaries are usually left in place during a fibroid hysterectomy, because they are healthy and removing them would trigger sudden surgical menopause. Keeping the ovaries preserves hormone function until natural menopause — discuss this explicitly with your surgeon rather than assuming, and ask about removable versus retained cervix too.

MR-guided focused ultrasound (MRgFUS, brand Exablate) uses focused ultrasound waves to heat and destroy fibroid tissue from outside the body, guided by real-time MRI — no incision and no general anaesthesia. It is available in a handful of Indian centres at roughly ₹2–4 lakh in 2026. Only about 20–30% of women are good candidates, treatment takes 3–4 hours, and some fibroid types respond poorly.

Radiofrequency ablation destroys a fibroid with heat delivered through a needle placed into it under image guidance. The transcervical approach is uterus-sparing and minimally invasive, with faster recovery than myomectomy, costing about ₹1.5–3 lakh and increasingly available in major Indian cities.

Several pharmacological approaches are still being studied, including vitamin D for prevention (of particular interest in India given widespread vitamin D deficiency) and green tea extract. The evidence is not yet strong enough to make these standard care, though correcting a documented vitamin D deficiency is sensible for many other reasons.

Whichever route you consider, the right choice is the one that fits your symptoms, age and fertility plans — not the newest technology for its own sake. If fibroids sit alongside another condition such as adenomyosis, treatment is planned together; our guide to adenomyosis treatment explains how.

Book an appointment if you notice any of the warning signs below. Most fibroid problems are not emergencies, but heavy bleeding and anaemia are easy to underestimate and worth checking early.

Seek same-day or emergency care if you are soaking through a pad or tampon every hour for several hours, passing very large clots, feeling faint, dizzy or breathless, or have severe sudden pelvic pain — this could mean dangerous blood loss or a fibroid that has lost its blood supply or twisted.

Indicative 2026 out-of-pocket costs: gynaecology consultation ₹500–2,500 privately (free or minimal at government hospitals); transvaginal ultrasound ₹1,000–3,000; pelvic MRI ₹6,000–12,000; tranexamic acid ₹50–200 per cycle; Mirena IUD ₹14,000–22,000 inserted; monthly Lupride injection ₹3,500–8,000; UAE ₹1.5–3 lakh; open myomectomy ₹50,000–1.5 lakh; laparoscopic myomectomy ₹80,000–2.5 lakh; hysterectomy ₹1–3 lakh.

Ayushman Bharat PM-JAY covers gynaecological surgery — including myomectomy, hysterectomy and UAE — for eligible families up to ₹5 lakh per family per year at empanelled hospitals, though it may not cover all medicines. CGHS, ECHS, ESI and railway schemes cover their members at empanelled hospitals.

Private health insurance generally covers surgery and inpatient care for fibroids, but cover for long-term hormone therapy (Mirena, monthly GnRH injections) varies and is often excluded. Pre-existing-condition waiting periods (commonly 2–4 years) may apply — read your policy and get procedures pre-authorised.

Public hospitals offering excellent fibroid care include the AIIMS network, PGI Chandigarh, JIPMER Puducherry, CMC Vellore, KEM Mumbai and state medical colleges; waiting times for elective surgery run 2–6 months. For UAE and focused ultrasound, large private chains (Apollo, Fortis, Manipal, Medanta, Max, Narayana) have the interventional-radiology expertise, which is steadily reaching tier-2 cities.

• WHO – Uterine fibroids fact sheet
• ACOG – Uterine Fibroids (FAQ)
• NHS – Fibroids
• FIGO classification of causes of abnormal uterine bleeding (FIGO/PALM-COEIN)
• Ayushman Bharat PM-JAY (National Health Authority)